Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial

Trial Profile

PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary) ; Palbociclib (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Goserelin; Letrozole; Pertuzumab; Tamoxifen; Trastuzumab
  • Indications Advanced breast cancer; Carcinoma
  • Focus Pharmacodynamics
  • Acronyms PETREMAC
  • Most Recent Events

    • 01 Sep 2022 Pooled analysis assessing HRD data detected by panel sequencing obtained as part of routine clinical care published in the Clinical Cancer Research
    • 23 Nov 2020 Protocol was amended mandating more potent chemotherapy regimens without PARP inhibition after the initial 10 weeks of olaparib monotherapy phase.
    • 23 Nov 2020 Results (n=32) assessing effectiveness of PARP inhibitors receiving initial olaparib monotherapy in treatment arms G/H published in the Annals of Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top